Femasys INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
Femasys Inc. reported continued operating losses and substantial doubt about its ability to continue as a going concern, alongside Nasdaq delisting notices, despite increased sales and product development progress.
NASDAQ
Femasys Inc. highlights advancements in its women's health portfolio, including regulatory approvals and strategic partnerships, in its annual 10-K filing.
NASDAQ
Femasys Inc. has filed an amendment to its annual report on Form 10-K to include previously omitted information regarding directors, executive compensation, and updated certifications.
NASDAQ
Femasys Inc.'s 10-K filing details the company's financial status, product development, and strategic initiatives in women's health, including FemaSeed and FemBloc.